leadf
logo-loader
viewIncanthera plc
(
AQSE:INC
)

Incanthera believe new skin cancer prevention cream reveals 'all positives and no negatives'

Incanthera PLC's (AQSE:INC) CEO Simon Ward and Kevin Hammond talk to Proactive London's Katie Pilbeam about new positive data from new skin permeation and sensitisation studies of its Sol skin cancer technology.

Both Simon and Kevin explain that Sol is a cream designed to deliver an active agent into the skin that is known to prevent the formation of solar (actinic) keratosis and skin cancer.

The results reveal that Sol is 'non-irritant' and comparable to baby sun protection products tested previously. They discuss the route to commercialism and hint at 'exciting conversations' happening behind closed doors.

Quick facts: Incanthera plc

Follow
AQSE:INC

Price: 12.55 GBX

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Incanthera present results of first full year as public company on AQSE

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive's Katie Pilbeam about their first full year as a public company on AQSE.  The highlights include discussions with two global cosmetic companies for Sol skin cancer technology which continue to progress.  Their technology...

on 18/5/21

2 min read